Compare Bank of America Corp (BAC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Cassava Sciences Inc — how do they compare? Bank of America Corp trades at $60.78 (market cap $425.43B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Bank of America Corp is far larger — about 8078.8× Cassava Sciences Inc's market cap, and Bank of America Corp pays a 1.85% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BAC | FLNA | |
|---|---|---|
Market Cap | $425.43B | $52.66M |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $4.64 |
52-Week Low | $44.92 | $1.09 |
Dividend Yield | 1.85% | — |
Enterprise Value | — | -$33.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $60.62, up 1.59% today, with a bullish technical signal from moving averages and a consensus analyst price target of $63.79. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.10 billion in 2025, and the company maintains a strong deposit franchise, as highlighted by recent news coverage.
The outlook is positive, supported by earnings momentum and potential capital returns post-stress tests. Risks include macroeconomic sensitivity and regulatory changes. Analyst sentiment is strongly bullish, with 65% recommending Buy.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
